{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1380021395963114526.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Kshama Mehta"}],"foaf:familyName":[{"@value":"Mehta"}],"foaf:givenName":[{"@value":"Kshama"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1360021395963113984","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1016/s0140-6736(23)00569-x"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S014067362300569X?httpAccept=text/xml"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S014067362300569X?httpAccept=text/plain"}],"notation":[{"@value":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/s0140-6736(23)00569-x_QTpAPJBn54e9XVjnMU4qdavnSwb"}]}